These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 38216940)

  • 1. Lipoprotein-associated phospholipase A2 predicts cardiovascular death in patients on maintenance hemodialysis: a 7-year prospective cohort study.
    Lin L; Teng J; Shi Y; Xie Q; Shen B; Xiang F; Cao X; Ding X; Xu X; Zhang Z
    Lipids Health Dis; 2024 Jan; 23(1):15. PubMed ID: 38216940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein-associated phospholipase A2 predicts cardiovascular events in dialyzed patients.
    De Mauri A; Vidali M; Chiarinotti D; Bellomo G; Rolla R
    J Nephrol; 2019 Apr; 32(2):283-288. PubMed ID: 30168082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationships between biological novel biomarkers Lp-PLA
    Chen Y; Wang S; Li J; Fu Y; Chen P; Liu X; Zhang J; Sun L; Zhang R; Li X; Liu L
    J Diabetes; 2024 Jul; 16(7):e13574. PubMed ID: 38924255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis.
    Garg PK; McClelland RL; Jenny NS; Criqui MH; Greenland P; Rosenson RS; Siscovick DS; Jorgensen N; Cushman M
    Atherosclerosis; 2015 Jul; 241(1):176-82. PubMed ID: 26004387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study.
    Tsimikas S; Willeit J; Knoflach M; Mayr M; Egger G; Notdurfter M; Witztum JL; Wiedermann CJ; Xu Q; Kiechl S
    Eur Heart J; 2009 Jan; 30(1):107-15. PubMed ID: 19019993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of lipoprotein-associated phospholipase A
    Han L; Zhong C; Bu X; Xu T; Wang A; Peng Y; Xu T; Wang J; Peng H; Li Q; Ju Z; Geng D; Zhang Y; He J;
    Atherosclerosis; 2017 Nov; 266():1-7. PubMed ID: 28934604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
    Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
    Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein profile, lipoprotein-associated phospholipase A2 and cardiovascular risk in hemodialysis patients.
    Rolla R; De Mauri A; Valsesia A; Vidali M; Chiarinotti D; Bellomo G
    J Nephrol; 2015 Dec; 28(6):749-55. PubMed ID: 25971848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein-associated phospholipase A₂ activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hypercholesterolemia.
    Mattina A; Rosenbaum D; Bittar R; Bonnefont-Rousselot D; Noto D; Averna M; Bruckert E; Giral P
    Nutr Metab Cardiovasc Dis; 2018 May; 28(5):517-523. PubMed ID: 29525223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
    O'Donoghue M; Morrow DA; Sabatine MS; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    Circulation; 2006 Apr; 113(14):1745-52. PubMed ID: 16537575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease.
    Xu RX; Zhang Y; Li XL; Li S; Guo YL; Dong Q; Liu G; Li JJ
    Clin Chim Acta; 2015 Jun; 446():195-200. PubMed ID: 25934512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study.
    White HD; Simes J; Stewart RA; Blankenberg S; Barnes EH; Marschner IC; Thompson P; West M; Zeller T; Colquhoun DM; Nestel P; Keech AC; Sullivan DR; Hunt D; Tonkin A;
    J Am Heart Assoc; 2013 Oct; 2(5):e000360. PubMed ID: 24152981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein-associated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in heart transplant patients.
    Raichlin E; McConnell JP; Bae JH; Kremers WK; Lerman A; Frantz RP
    Transplantation; 2008 Apr; 85(7):963-8. PubMed ID: 18408575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Extended-Release Niacin on Quartile Lp-PLA
    Lyubarova R; Albers JJ; Marcovina SM; Yao Y; McBride R; Topliceanu A; Anderson T; Fleg JL; Desvigne-Nickens P; Kashyap ML; McGovern ME; Boden WE
    J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):534-541. PubMed ID: 31131629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of obesity and cardiometabolic makers on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in adolescents: the healthy young cross-sectional study.
    da Silva IT; Timm Ade S; Damasceno NR
    Lipids Health Dis; 2013 Feb; 12():19. PubMed ID: 23413990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection.
    Ross Eckard A; Longenecker CT; Jiang Y; Debanne SM; Labbato D; Storer N; McComsey GA
    HIV Med; 2014 Oct; 15(9):537-46. PubMed ID: 24650269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
    Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Heiss G; Sharrett AR
    Circulation; 2004 Feb; 109(7):837-42. PubMed ID: 14757686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress.
    Koenig W; Twardella D; Brenner H; Rothenbacher D
    Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1586-93. PubMed ID: 16627803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of lipoprotein-associated phospholipase A2 for prediction of 30-day major adverse coronary event in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
    Stankovic S; Asanin M; Trifunovic D; Majkic-Singh N; Miljković A; Ignjatovic S; Mrdovic I; Matic D; Savic L; Ostojic M; Vasiljevic Z
    Clin Lab; 2012; 58(11-12):1135-44. PubMed ID: 23289182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein-associated phospholipase A
    Öngen B; Kalkan Uçar S; Levent E; Azarsız E; Koloğlu T; Çoker M; Sözmen E; Sağın FG
    Ann Clin Biochem; 2017 Sep; 54(5):539-547. PubMed ID: 27614353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.